ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
The Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching a clinical programme for an antibiotic.
The London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune.
French Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheim’s consumer healthcare (CHC) business in exchange for Sanofi’s animal health arm Merial.
Electronic submission systems of the Innovative Medicines Initiative (IMI) will open for biotech companies and research groups on 4 January 2017 to apply for collaborative projects with pharma partners under the IMI scheme.
Indigo Diabetes NV has been spun-off from University of Ghent and international research institute imec with a series A financing of €7m. The company’s needle-free glucose sensor addresses a €12bn market.
The Europan Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted therapies for EU market authorisation.
Neurology specialist Celgene has nailed down access to Evotec’s induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases.
Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.
Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance.
Roche’s US subsidiary Genentech has acquired an exclusive option to commercialise Novimmune’s TLR4 antibody NI-0101, the very first personalised approach to treat rheumatoid arthritis. The compound has already proved safety and drugability in a Phase I dose escalation trail.